US FDA approves Novo Nordisk's Ozempic to cut risk of diabetic kidney disease progression
The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as death due to heart problems in diabetes patients with chronic kidney disease (CKD),
The biggest development in weight-loss medicine since bariatric surgery (not to mention ... A spokesperson for the FDA ...
Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...
Current laws and regulations are not enough to protect Americans from the risks of compounded versions of popular weight loss ...
As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has ...
The newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ...
In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help ...
A multi-million dollar Super Bowl ad from telehealth company Hims and Hers downplays risks and side effects of compounded ...
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback